North China Pharmaceutical Co Ltd (600812) — Cash Flow-to-Debt Ratio
North China Pharmaceutical Co Ltd (600812) has a Cash Flow-to-Debt Ratio of 0.01x as of September 2025, meaning its operating cash flow of CN¥170.24 Million could theoretically repay 0% of its total liabilities (CN¥14.86 Billion) in one year. See North China Pharmaceutical Co Ltd leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
North China Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (1998–2025)
Historical debt coverage capacity for North China Pharmaceutical Co Ltd across 28 annual periods. For the full cash flow conversion analysis, see North China Pharmaceutical Co Ltd cash conversion from operations.
Annual Cash Flow-to-Debt Ratio for North China Pharmaceutical Co Ltd (1998–2025)
Year-by-year debt coverage analysis for North China Pharmaceutical Co Ltd. Check North China Pharmaceutical Co Ltd (600812) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.08x | CN¥1.18 Billion | CN¥14.51 Billion | ▼ -2.4% |
| 2024 | 0.08x | CN¥1.23 Billion | CN¥14.80 Billion | ▲ +19.1% |
| 2023 | 0.07x | CN¥1.02 Billion | CN¥14.69 Billion | ▲ +4.1% |
| 2022 | 0.07x | CN¥1.00 Billion | CN¥14.99 Billion | ▲ +14.3% |
| 2021 | 0.06x | CN¥1.05 Billion | CN¥17.91 Billion | ▲ +31.6% |
| 2020 | 0.04x | CN¥752.15 Million | CN¥16.88 Billion | ▼ -21.5% |
| 2019 | 0.06x | CN¥732.97 Million | CN¥12.92 Billion | ▼ -9.1% |
| 2018 | 0.06x | CN¥774.33 Million | CN¥12.40 Billion | ▲ +158.0% |
| 2017 | 0.02x | CN¥287.25 Million | CN¥11.87 Billion | ▲ +160.6% |
| 2016 | -0.04x | CN¥-446.53 Million | CN¥11.18 Billion | ▼ -449.6% |
| 2015 | 0.01x | CN¥122.50 Million | CN¥10.73 Billion | ▲ +30.1% |
| 2014 | 0.01x | CN¥90.56 Million | CN¥10.32 Billion | ▲ +167.7% |
| 2013 | -0.01x | CN¥-135.03 Million | CN¥10.41 Billion | ▼ -89.9% |
| 2012 | -0.01x | CN¥-63.92 Million | CN¥9.36 Billion | ▼ -129.9% |
| 2011 | 0.02x | CN¥227.60 Million | CN¥9.95 Billion | ▲ +130.3% |
| 2010 | -0.08x | CN¥-598.35 Million | CN¥7.94 Billion | ▼ -147.8% |
| 2009 | 0.16x | CN¥1.01 Billion | CN¥6.41 Billion | ▼ -22.0% |
| 2008 | 0.20x | CN¥1.09 Billion | CN¥5.37 Billion | ▲ +58.8% |
| 2007 | 0.13x | CN¥664.37 Million | CN¥5.22 Billion | ▲ +19.8% |
| 2006 | 0.11x | CN¥597.12 Million | CN¥5.61 Billion | ▲ +163.2% |
| 2005 | 0.04x | CN¥224.17 Million | CN¥5.55 Billion | ▼ -23.3% |
| 2004 | 0.05x | CN¥310.39 Million | CN¥5.89 Billion | ▼ -59.1% |
| 2003 | 0.13x | CN¥580.32 Million | CN¥4.51 Billion | ▼ -25.2% |
| 2002 | 0.17x | CN¥738.50 Million | CN¥4.29 Billion | ▲ +117.1% |
| 2001 | 0.08x | CN¥367.28 Million | CN¥4.63 Billion | ▲ +94.0% |
| 2000 | 0.04x | CN¥133.49 Million | CN¥3.27 Billion | ▲ +131.7% |
| 1999 | -0.13x | CN¥-373.62 Million | CN¥2.90 Billion | ▲ +20.8% |
| 1998 | -0.16x | CN¥-326.74 Million | CN¥2.01 Billion | — |